ERBB2 and breast cancer: When patients with HER2-low BC were randomly assigned to receive adjuvant chemotherapy or chemotherapy and trastuzumab, results from the phase 3 NSABP B47 trial demonstrated no survival improvement with the addition of trastuzumab in HER2-low early-stage BC [3].